SecBot SecBot
Biotech Drug Report Generated Oct 28, 2026

felcorekibart

GSK·GSK plc
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 3
Time to market
Phase 3 trials started in August-September 2026 with estimated primary completion around July 2029 for the COPD studies and similar timelines for asthma and nasal polyps. If successful, a regulatory filing would likely follow in 2029-2030, with potential approval in the 2030-2031 timeframe.
Why 4/10
The next hard, dated catalysts are the Phase 3 primary completion dates (~July 2029 for the COPD trials, similar timelines for asthma and nasal polyps), which are more than two years away. No PDUFA, pivotal readout or Advisory Committee date is scheduled within the next 12 months. GSK is a large diversified pharma, so even a successful Phase 3 readout in ~2029 would be one data point among many. ImpactScore is 4 per the default floor for an early-stage Phase 3 asset at a large cap with no near-term binary.
Actionable Insight NEUTRAL

Felcorekibart's Phase 3 PERSIST programme (six trials across COPD, asthma and nasal polyps) began enrollment in August-September 2026, with primary completion estimated around mid-2029. No top-line data, regulatory submission or PDUFA date is scheduled within the next 12 months, so the drug is not a near-term price catalyst for GSK. Investors should watch for any Phase 2 dose-finding data from the earlier asthma study (NCT05593250) as the next potential readout, but that trial's status is active/not recruiting with no posted results yet.

Price Chart

Loading chart...

Executive Summary

Felcorekibart (GSK5784283, also known as AIO-001 and SHR-1905) is a long-acting, twice-yearly injectable antibody that blocks the inflammatory protein TSLP, making it a direct competitor to AstraZeneca/Amgen's Tezspire (tezepelumab). Originally developed by China's Jiangsu Hengrui, it was licensed to Aiolos Bio and then acquired by GSK in February 2024 for $1B upfront plus up to $400M in milestones. In 2026, GSK launched the broad PERSIST Phase 3 programme of six pivotal trials across COPD, uncontrolled asthma, and chronic rhinosinusitis with nasal polyps, all of which began enrollment in August-September 2026. Primary completion is estimated around mid-2029, meaning no near-term binary catalyst exists. For GSK as a large cap, felcorekibart is one of several pipeline assets with long-term potential but no near-term share-price impact.

How It Works

Felcorekibart is a laboratory-made antibody (a 'biologic' drug) that blocks a protein called TSLP. TSLP is released by cells lining the lungs and airways when they encounter triggers like allergens, viruses or pollution. It acts like an 'alarm signal' that starts a chain reaction of inflammation. By blocking TSLP, felcorekibart aims to prevent this inflammatory cascade before it begins, which could reduce asthma attacks and COPD flare-ups. The drug is designed to be long-acting, potentially requiring injections only twice a year.

Trial Status

GSK initiated six Phase 3 PERSIST trials in mid-2026: PERSIST COPD-1 and COPD-2 (624 patients each, started Aug-Sep 2026); PERSIST ASTHMA-1 (514 patients, started Aug 2026) and ASTHMA-2; and PERSIST CRSwNP-1 and CRSwNP-2 (218 patients each, started Sep 2026). All trials are actively recruiting. An earlier Phase 2 dose-finding study (NCT05593250, originally SHR-1905) in severe uncontrolled asthma is listed as active but no longer recruiting, with no published results.

The Two-Sided Case

▲ Bull Case4
Felcorekibart is designed as a long-acting anti-TSLP antibody with potential twice-yearly subcutaneous dosing, which could offer a significant convenience advantage over Tezspire (monthly dosing) if proven in trials.
The TSLP inhibitor market is growing rapidly: the global TSLP monoclonal antibody market was estimated at $1.94B in 2025 and projected to reach $7.8B by 2034 (14.4% CAGR). Tezspire's strong adoption validates the mechanism and leaves room for multiple entrants.
GSK has initiated an aggressive, broad Phase 3 PERSIST programme of six trials across three indications (COPD, uncontrolled asthma, and chronic rhinosinusitis with nasal polyps), expanding the drug's addressable market beyond severe asthma alone.
CEO Luke Miels singled out felcorekibart as a key pipeline programme, and GSK's Q3 2026 earnings call confirmed increased R&D investment partly driven by felcorekibart spend, signalling internal confidence.
▼ Bear Case4
Felcorekibart enters a crowded TSLP-targeting field already led by AstraZeneca/Amgen's Tezspire (tezepelumab), which generated ~$474M in Q4 2025 sales (~$1.9B annualised) and is growing 52-60% year-over-year. Other competitors such as Roche's lunsekimig (TSLPxIL-33 bispecific) and Windward Bio's WIN378 are also in development.
GSK's Phase 3 trials just began enrolling (August-September 2026); primary completion is estimated at mid-2029, meaning a potential approval would be years away with no near-term revenue contribution.
The drug originally came from Jiangsu Hengrui via Aiolos Bio, which GSK acquired for $1B upfront plus up to $400M in milestones. No Phase 2 efficacy data from a GSK-sponsored study has been publicly reported yet, so the drug's differentiation versus Tezspire remains unproven.
As a large cap (~$100B+ market cap), felcorekibart is one asset among many in GSK's pipeline; even positive data would be diluted across the company's broad respiratory/oncology/vaccines portfolio.

Upcoming Catalysts

  • Potential publication of Phase 2 dose-finding data from the earlier SHR-1905 asthma study (NCT05593250), though no timeline is announced
  • Initiation of any remaining PERSIST trials (ASTHMA-2 already registered but start details less clear)
  • Regulatory updates on the TSLP inhibitor class, especially Tezspire label expansions into COPD and nasal polyps that could set precedent

Source Filing

The SecBot filing or press-release report that triggered this drug report:

GSK plc 6-K GSK ·Originating report

Sources · 19

Hover a chip for the title
1 gsk.com2 investegate.co.uk3 reuters.com4 gsk.com5 tipranks.com6 firstwordpharma.com7 trialticker.com8 trialticker.com9 trialticker.com10 adisinsight.springer.com11 researchandmarkets.com12 intelmarketresearch.com13 en.edaily.co.kr14 stockanalysis.com15 gsk-studyregister.com16 gsk-studyregister.com17 clinicaltrials.gov18 clinicaltrials.gov19 clinicaltrials.gov